+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase



Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase



Clinical Cancer Research 6(4): 1322-1327



We had previously shown that high gene expressions (mRNA levels) of thymidylate synthase (TS; Leichman et al., J. Clin. Oncol., 15: 3223-3229, 1997) and thymidine phosphorylase (TP; Metzger et al., Clin. Cancer Res., 4: 2371-2376, 1998) in pretreatment tumor biopsies could identify tumors that would be nonresponsive to 5-fluorouracil (5-FU)-based therapy. In this study, we investigated the association between intratumoral gene expression of the pyrimidine catabolism enzyme dihydropyrimidine dehydrogenase (DPD) and the response of colorectal tumors to the same 5-FU-based protocol. DPD expressions were measured by quantitative reverse transcription-PCR in 33 pretreatment biopsies of colorectal tumors from patients who went on to receive treatment with 5-FU and leucovorin (LV). The range of DPD gene expression in those tumors that were nonresponsive to 5-FU was much broader than that of the responding tumors. None of the tumors with basal-level DPD expressions above a DPD:beta-actin ratio of 2.5 x 10(-3) (14 of 33) were responders to 5-FU/LV therapy, whereas those tumors with DPD gene expressions below DPD: beta-actin ratio of 2.5 x 10(-3) had a response rate of 50%. There was no correlation among DPD, TS, and TP expression values in this set of colorectal tumors, which indicated that these gene expressions are independent variables. All of the tumors that responded to 5-FU therapy (11 of 33) had expression values of all three of the genes, TS, TP, and DPD, below their respective nonresponse cutoff values, whereas, in each of the nonresponding tumors, at least one of these gene expressions was high. The patients with low expression of all three of the genes had significantly longer survival than patients with a high value of any one of the gene expressions. The results of this study show that intratumoral gene expression level of DPD is associated with tumor response to 5-FU and that the use of more than one independent determinant of response permits the identification of a high percentage of responding patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045565635

Download citation: RISBibTeXText

PMID: 10778957


Related references

Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer. International Journal of Clinical and Experimental Pathology 8(10): 12333-12345, 2015

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 70(5): 366-377, 2006

Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer. Anticancer Research 32(5): 1757-1762, 2012

Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Annals of Oncology 19(5): 915-919, 2008

Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. International Journal of Colorectal Disease 21(3): 238-247, 2006

Expression of mRNA levels of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in diffusely infiltrating colorectal cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(7): 1073-1077, 2007

Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients. Pharmacogenetics and Genomics 16(11): 809-816, 2006

Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncology Reports 11(1): 9, 2004

Thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), ERCC1, & thymidine phosphorylase gene expression in primary & metastatic (met) colorectal cancer (CRC) tissue in patients (pts) treated on a phase I trial of oxaliplatin (OX) & capecitabine (Xel). Journal of Clinical Oncology 23(16_Suppl): 3549-3549, 2016

Comparative analysis of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in colorectal cancer and surrounding normal tissue. Neoplasma 52(3): 208-210, 2005

Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy. Molecular and Clinical Oncology 1(6): 987-994, 2013

Thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase-gene expression in primary gastric cancer and metastatic sites. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1001, 2003

Thymidine phosphorylase expression in colorectal tumors together with that of thymidylate synthase predict tumor response to 5-fluorouracil. Proceedings of the American Association for Cancer Research Annual Meeting 38: 614-615, 1997

Importance of cellular localization of dihydropyrimidine dehydrogenase, thymidine phosphorylase and thymidylate synthase in colorectal cancer. Proceedings of the American Association for Cancer Research Annual Meeting 44: 119-120, 2003

Prognostic value of thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase in nodal negative colorectal carcinomas. Pathology Research & Practice 198(3): 232, 2002